Loading organizations...
§ Private Profile · Edinburgh, Edinburgh, United Kingdom
Develops fluorescent imaging agents for real-time molecular imaging in diagnostics, enabling image-guided therapy.
Based in Edinburgh, Scotland, Edinburgh Molecular Imaging develops fluorescent optical imaging agents designed to diagnose cancerous lesions, inflammatory diseases, and lung infections during image-guided therapy. The company's proprietary technology targets diseased tissue in real time, allowing clinicians to perform precise surgical interventions and medical diagnostics while sparing healthy areas. Operating with fewer than 25 employees, the enterprise currently generates approximately $9.3 million in annual reported revenue. The firm has successfully secured over £15 million in non-dilutive grant funding from organizations such as the Wellcome Trust and the Medical Research Council, alongside a £4 million Series A venture capital investment led by Epidarex Capital and the Scottish Investment Bank. Edinburgh Molecular Imaging was founded in 2014 as a spin-out from the University of Edinburgh by Professor Mark Bradley, Professor Chris Haslett, and Dr. Kev Dhaliwal.
Edinburgh Molecular Imaging has raised $6.6M across 1 funding round.
Edinburgh Molecular Imaging has raised $6.6M in total across 1 funding round.
Edinburgh Molecular Imaging has raised $6.6M in total across 1 funding round.
Edinburgh Molecular Imaging's investors include Epidarex Capital, Scottish Enterprise.
Edinburgh Molecular Imaging has raised $6.6M across 1 funding round. Most recently, it raised $6.6M Series A in February 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 8, 2014 | $6.6M Series A | — | Epidarex Capital, Scottish Enterprise | Announced |